Kiniksa Pharmaceuticals Analyst Ratings
Kiniksa Pharmaceuticals Analyst Ratings
Kiniksa Pharmaceuticals Analyst Ratings
Buy Rating Affirmed for Kiniksa Pharmaceuticals Amid Strong Q1 Performance and Promising Drug Prospects
Buy Rating Affirmed for Kiniksa Pharmaceuticals Amidst Growth Potential and Strong Commercial Execution
Kiniksa Pharmaceuticals (KNSA) Receives a Buy From Goldman Sachs
Analysts Are Bullish on These Healthcare Stocks: G1 Therapeutics (GTHX), Kiniksa Pharmaceuticals (KNSA)
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Rhythm Pharmaceuticals (RYTM) and Kiniksa Pharmaceuticals (KNSA)
Strong Arcalyst Sales and Promising Pipeline Reinforce Kiniksa Pharmaceuticals Buy Rating
Kiniksa Pharmaceuticals Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Kiniksa Pharmaceuticals (KNSA) and UnitedHealth (UNH)
Promising Growth and Strategic Investments Bolster Buy Rating for Kiniksa Pharmaceuticals
J.P. Morgan Sticks to Its Buy Rating for Kiniksa Pharmaceuticals (KNSA)
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $32
Kiniksa Pharmaceuticals Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: Tarsus Pharmaceuticals (TARS), Kiniksa Pharmaceuticals (KNSA) and Danaher (DHR)
Goldman Sachs Sticks to Their Buy Rating for Kiniksa Pharmaceuticals (KNSA)
Wedbush Adjusts Kiniksa Pharmaceuticals Price Target to $23 From $21, Maintains Outperform Rating
Goldman Sachs Sticks to Its Buy Rating for Kiniksa Pharmaceuticals (KNSA)
Wedbush Raises Kiniksa Pharmaceuticals Price Target to $21 From $20, Maintains Outperform Rating